

06-20-01

GP/1636

EXPRESS MAIL CERTIFICATE

Date

6/19/01

Label No.

EL 706743439 EL

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 1-10

RECEIVED

JUN 22 2001

TECH CENTER 1600/2900

Name (Print)

Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No: 0630/1E791-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Vedrana SUSULIC; Emir DUZIC

Serial No.: 09/761/116

Art Unit: 1636

Confirmation No.: 3094

Filed: January 16, 2001

Examiner:

For: TRANSCRIPTIONAL REGULATION OF THE HUMAN BETA3
ADRENERGIC RECEPTOR GENE

RESPONSE TO OFFICE ACTION

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

June 19, 2001

Sir:

This submission responds to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 7, 2001 (copy enclosed). The time set for this response is August 7, 2001.

IN THE SPECIFICATION:

Please include the enclosed copy of the Sequence Listing in the specification of this application.

REMARKS


It was noted in the enclosed Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures that the divisional application filed on January 16, 2001, failed to comply with the requirements set forth in 37 C.F.R. §1.821 through §1.825. Specifically, the absence of submission of a computer readable form (CRF) copy of the Sequence Listing and a paper or compact disc copy of the Sequence Listing was cited.

STATEMENT PURSUANT TO 37 C.F.R. §1.821

Pursuant to 37 C.F.R. §1.821, applicants herein state that the contents of the enclosed paper entitled "SEQUENCE LISTING," are identical to that filed in the computer readable form in parent Application No. 09/243,335, filed February 1, 1999, now U.S. patent No. 6,197,580, and that the sequence submission contains no new matter. In accordance with 37 C.F.R. §1.821(e), please use the last filed computer readable form filed in that application as the computer readable form in this application. A copy of the sequence listing is included herewith and inserted into the specification in this amendment.

Consideration of this response forwarding the enclosed paper copy of the
sequence listing is respectfully requested.

Respectfully submitted,



Paul F. Fehlner, Ph.D.

Reg. No. 35,135

Attorney for Applicants

DARBY & DARBY, P.C.
805 Third Avenue
New York, N.Y. 10022
Phone (212) 527-7700

::ODMA\WORLD\DOX\M:\0630\1E791US1\SRA0042.WPD